close
Prolia®:Denosumab,the first FDA-approved RANK Ligand inhibitor
Prolia® targets and binds to RANK Ligand, inhibiting osteoclast formation, function and survival.
Thus, Prolia® can help keep osteoclasts from resorbing bone.
全站熱搜
留言列表